A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Principal Investigator
Louis Fehrenbacher, MD
Status
Complete
Date Opened To Accrual
January 06 2011
Date Closed to Accrual
February 10 2015
Disease Site
Breast [BR]
Breast
Phase
III
Developmental Therapeutics
No
Primary Objective
To determine whether the addition of trastuzumab to chemotherapy (TC or AC → WP) improves invasive disease-free survival (IDFS) in women with resected node-positive or high-risk node-negative breast cancer which is reported as HER2-low by all HER2 testing performed.
Patient Population
Women with Resected Node-Positive or High-Risk Node-Negative Invasive Breast Cancer Determined to be HER2-Low
Target Accrual
3260
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.